The Zhitong Finance App learned that in the biotechnology sector, progress in drug research and development is certainly a core variable in stock prices, but the trading trends of company insiders are also an important factor in observing the company's prospects. Seen from this perspective, the operations of four company insiders, Capricorn (CAPR.US), ImmunityBio (IBRX.US), Sellas (SLS.US), and Iovance (IOVA.US), showed a very different picture: some cashed out, some bought against the trend, and others stayed on hold.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.